Tempest Therapeutics, Inc. — Form 8-K
Filed September 17, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Tempest Therapeutics entered an exclusive option agreement with Hebei Senlang Biotechnology on September 14, 2026, to license Senlang's CD7-targeted lentiviral vector platform and in vivo CAR-T product candidates. The portfolio includes a BCMA/GPRC5D dual-targeting candidate in Phase 1 for multiple myeloma. Financial terms: Tempest pays an initial license fee upon option exercise, quarterly maintenance fees during collaboration term (3 years post-exercise), royalties on net sales until $800M cumulative royalties paid per product, and 20% of sublicense fees. Senlang retains rights in Greater China only.
Why this rating
Material deal for $30M company; adds clinical-stage asset with dual-target platform; expands pipeline but execution risk remains on royalty burden.
Tradability signal
NO TRADE
No trade: the filing reads positive but the market is selling it (-5.0% since it hit EDGAR) — when our read and the tape disagree this hard, we stand aside. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $0.90 ▲ 0.00% | at our read · unknown $0.90 | +10 min · unknown $0.93 ▲ 3.69% | +30 min · unknown $1.05 ▲ 17.32% | +1 hr · unknown $1.04 ▲ 16.20% | +4 hrs · unknown $0.94 ▲ 4.47% |
The stock had already moved +0.00% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.